NO942813D0 - Spröytekjölt nabumeton - Google Patents

Spröytekjölt nabumeton

Info

Publication number
NO942813D0
NO942813D0 NO942813A NO942813A NO942813D0 NO 942813 D0 NO942813 D0 NO 942813D0 NO 942813 A NO942813 A NO 942813A NO 942813 A NO942813 A NO 942813A NO 942813 D0 NO942813 D0 NO 942813D0
Authority
NO
Norway
Prior art keywords
pct
spray
nabumeton
peeled
sec
Prior art date
Application number
NO942813A
Other languages
English (en)
Norwegian (no)
Other versions
NO942813L (no
Inventor
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO942813D0 publication Critical patent/NO942813D0/no
Publication of NO942813L publication Critical patent/NO942813L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coating By Spraying Or Casting (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Road Signs Or Road Markings (AREA)
  • Catching Or Destruction (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO942813A 1992-01-29 1994-07-28 Spröytekjölt nabumeton NO942813L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929201857A GB9201857D0 (en) 1992-01-29 1992-01-29 Novel compound
PCT/GB1993/000145 WO1993014747A1 (en) 1992-01-29 1993-01-22 Spray-chilled nabumetone

Publications (2)

Publication Number Publication Date
NO942813D0 true NO942813D0 (no) 1994-07-28
NO942813L NO942813L (no) 1994-07-28

Family

ID=10709436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942813A NO942813L (no) 1992-01-29 1994-07-28 Spröytekjölt nabumeton

Country Status (24)

Country Link
US (1) US5539000A (xx)
EP (1) EP0624087B1 (xx)
JP (1) JPH07503245A (xx)
KR (1) KR950700056A (xx)
CN (1) CN1079954A (xx)
AT (1) ATE150298T1 (xx)
AU (1) AU3362693A (xx)
BG (1) BG98933A (xx)
BR (1) BR9305674A (xx)
CA (1) CA2129027A1 (xx)
CZ (1) CZ182894A3 (xx)
DE (1) DE69309037T2 (xx)
DK (1) DK0624087T3 (xx)
ES (1) ES2099419T3 (xx)
FI (1) FI943550A0 (xx)
GB (1) GB9201857D0 (xx)
GR (1) GR3023142T3 (xx)
HU (1) HUT67462A (xx)
IL (1) IL104526A0 (xx)
MX (1) MX9300430A (xx)
NO (1) NO942813L (xx)
SK (1) SK91694A3 (xx)
WO (1) WO1993014747A1 (xx)
ZA (1) ZA93577B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US20020132010A1 (en) * 2000-12-22 2002-09-19 Yihong Qui Divalproex sodium dosage forms and a process for their production
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
ES2308274T3 (es) * 2003-12-04 2008-12-01 Pfizer Products Inc. Procedimiento para fabricar multiparticulados farmaceuticos.
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
WO2007022445A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA3224506A1 (en) 2010-05-12 2011-11-17 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
US4086346A (en) 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
DE3833446A1 (de) 1988-10-01 1990-04-05 Hoechst Ag Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten

Also Published As

Publication number Publication date
CN1079954A (zh) 1993-12-29
EP0624087B1 (en) 1997-03-19
SK91694A3 (en) 1995-03-08
HU9402221D0 (en) 1994-09-28
DE69309037D1 (de) 1997-04-24
DK0624087T3 (da) 1997-09-01
CZ182894A3 (en) 1995-02-15
BG98933A (en) 1995-07-28
ZA93577B (en) 1994-01-13
ATE150298T1 (de) 1997-04-15
KR950700056A (ko) 1995-01-16
US5539000A (en) 1996-07-23
AU3362693A (en) 1993-09-01
IL104526A0 (en) 1993-05-13
NO942813L (no) 1994-07-28
FI943550A (fi) 1994-07-28
JPH07503245A (ja) 1995-04-06
HUT67462A (en) 1995-04-28
CA2129027A1 (en) 1993-08-05
GB9201857D0 (en) 1992-03-18
BR9305674A (pt) 2005-01-11
FI943550A0 (fi) 1994-07-28
MX9300430A (es) 1994-08-31
DE69309037T2 (de) 1997-07-24
GR3023142T3 (en) 1997-07-30
ES2099419T3 (es) 1997-05-16
WO1993014747A1 (en) 1993-08-05
EP0624087A1 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
NO942813L (no) Spröytekjölt nabumeton
EP0602790A3 (en) Directing operation of computer systems.
EP0592808A3 (en) Masking of commercial data.
FR2689717B1 (fr) Dispositif d'application de micro-ondes et reacteur a plasma utilisant ce dispositif.
IL113141A0 (en) Intermediates for hypoglycemic hydroxyurea detivatives
PH31249A (en) Inhibitors of hiv protease.
SE9002468D0 (sv) A device and method for dosing a liquid product
MX9709398A (es) N-aril-1,2,4-triazolin-5-onas.
NO973366L (no) Fremgangsmåte for behandling av multippel sklerose
TW328540B (en) 3-azidomethyl-3-nitratomethyloxetane and polymers formed therefrom
EP0828493A4 (en) 4.4-DISUBSTITUTED CYCLOHEXANE-1-OL MONOMERS AND RELATED COMPOUNDS
WO1996026728A3 (en) Use of moxonidine for the treatment of atherosclerosis
AU7962091A (en) Phenyl 4-guanidinobenzoate derivative, process for producing the same, and protease inhibitor containing the same
TW342311B (en) Fungicidal mixtures
ZA936861B (en) Methods and agents for combating cockroaches.
FI953568A0 (fi) Kytkimen suojausjärjestely
TW366338B (en) Arylalkoxyphenoxy-imidazoline compounds
EP0646373A3 (en) Epstein-Barr virus expression inhibitor.
NO954115L (no) Anvendelse av ceruletid-dietylaminsalt ved behandling av psoriasis
EP0799176A4 (en) 4.4- (DISUBSTITUTED) CYCLOHEXAN-1-ONE DIMERS AND RELATED COMPOUNDS
ES1021888Y (es) Manguera contra incendios.
ZA963296B (en) A novel use of (S)-adenosyl-l-methionine (SAMe).
AU645723B2 (en) Large scale, non-chromatographic purification of chromogenic cryptahemispherands (1.1) and (2.1)
KR940018438U (ko) 피.오.피(p.o.p) 발생회로
HUT75125A (en) Bagameri mamut variety of horse radish (armoratia lapathifolia, gilib)